Eversheds Sutherland advises Pacira BioSciences, Inc., on its acquisition of GQ Bio Therapeutics

Eversheds Sutherland advised Pacira BioSciences on the German law aspects of the transaction.

Pacira acquired the outstanding stake in GQ Bio from the founders and venture capital investors like High-Tech Gründerfonds and IFB Innovationsstarter GmbH. This transaction builds upon Pacira’s previous investments in GQ Bio, as well as the two companies’ partnership for the development of a commercially scalable manufacturing process for PCRX-201 (enekinragene inzadenovec) and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform.

GQ Bio is a privately held biopharmaceutical company with a novel, high-capacity, local-delivery platform that makes genetic medicines more efficient and enables the use of large and multiple gene constructs. GQ Bio also brings to Pacira a preclinical portfolio of assets with disease-modifying potential in prevalent musculoskeletal diseases, and research and development talent.

The Eversheds Sutherland team was co-led by Partners Robin Johnson in the UK, Dr. Christian Mense and Dr. Christian Lindner in Germany.